Cergentis is a trusted genomics-focused biotech company providing services and in-house solutions based on its proprietary genomic analysis platform to all leading biopharmaceutical companies and renowned research institutes. With our widely published and recognized genetic analyses, we support our global customer base in the characterization and QC of their genetically engineered models, biopharmaceutical cell line development and cell- and gene therapy products. By helping to de-risk R&D program decisions, minimizing time-to-clinic, providing objective genomic evidence for regulators, and supporting patient safety, we aim to support biopharmaceutical medicine development programs worldwide. For more information, visit cergentis.com. Cergentis is a spin-off from Wouter de Laat's lab at Hubrecht Institute and KNAW in 2012. Cergentis has been acquired by Solvias in July 2022.